title: Preventive effectiveness of implantable cardioverter defibrillator in reducing sudden cardiac death in the Chinese population: a multicenter trial of ICD therapy versus non-ICD therapy.
abstract: Preventive Effectiveness of Implantable Cardioverter.
  
  
  BACKGROUND
  This prospective and multicenter trial of the implantable cardioverter-defibrillator (ICD) aimed to evaluate the mortality rate (including sudden cardiac death [SCD]) and the efficacy of ICD in Chinese patients with high risk of sudden death.
  
  
  RESULTS
  This trial was conducted in 31 centers in China. We enrolled 497 patients who fulfilled Class I indication for ICD (2002 ACC/AHA/NASPE guideline). All patients were followed-up at 3, 6, and 12 months. Clinical characteristics and echocardiographic parameters were collected at baseline and follow-up; Kaplan-Meier survival analysis was performed. Among 497 enrolled patients with Class I indication of ICD therapy, 112 (22.5%) agreed to and received ICD implantation (ICD group). The remaining 385 patients who were not available for ICD therapy were designated as the non-ICD group. During a mean follow-up of 11 ± 3 months, there were a total of 38 deaths, 2 in the ICD group with a mortality of 1.8% and 36 in the non-ICD group, with a mortality of 9.4% and 26 due to SCD. The overall survival rate was 93% at 3 months of follow-up, 91% at 6 months, and 89% at 12 months, with an incidence of SCD of 5%, 7%, and 8% at 3, 6, and 12 months, respectively.
  
  
  CONCLUSIONS
  In patients with Class I indication of ICD implantation, the total mortality and incidence of SCD were high. ICD therapy can effectively reduce the mortality in such patients.
authors.affiliation: Cardiac Arrhythmia Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. drhua1@hotmail.com
authors.forename: Wei
authors.initials: W
authors.lastname: Hua
authors.forename: Hongxia
authors.initials: H
authors.lastname: Niu
authors.forename: Xiaohan
authors.initials: X
authors.lastname: Fan
authors.forename: Ligang
authors.initials: L
authors.lastname: Ding
authors.forename: Yi-Zhou
authors.initials: YZ
authors.lastname: Xu
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Keping
authors.initials: K
authors.lastname: Chen
authors.forename: Fangzheng
authors.initials: F
authors.lastname: Wang
authors.forename: Shu
authors.initials: S
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D002681:China / Q000453:epidemiology; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D004554:Electric Countershock / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011474:Prosthesis Design; D012307:Risk Factors; D017180:Tachycardia, Ventricular / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*